161 related articles for article (PubMed ID: 18205948)
21. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH
Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326
[TBL] [Abstract][Full Text] [Related]
22. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.
Melnick A; Carlile GW; McConnell MJ; Polinger A; Hiebert SW; Licht JD
Blood; 2000 Dec; 96(12):3939-47. PubMed ID: 11090081
[TBL] [Abstract][Full Text] [Related]
23. Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity.
Wichmann C; Becker Y; Chen-Wichmann L; Vogel V; Vojtkova A; Herglotz J; Moore S; Koch J; Lausen J; Mäntele W; Gohlke H; Grez M
Blood; 2010 Jul; 116(4):603-13. PubMed ID: 20430957
[TBL] [Abstract][Full Text] [Related]
24. The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein.
Melnick AM; Westendorf JJ; Polinger A; Carlile GW; Arai S; Ball HJ; Lutterbach B; Hiebert SW; Licht JD
Mol Cell Biol; 2000 Mar; 20(6):2075-86. PubMed ID: 10688654
[TBL] [Abstract][Full Text] [Related]
25. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors.
Lutterbach B; Westendorf JJ; Linggi B; Patten A; Moniwa M; Davie JR; Huynh KD; Bardwell VJ; Lavinsky RM; Rosenfeld MG; Glass C; Seto E; Hiebert SW
Mol Cell Biol; 1998 Dec; 18(12):7176-84. PubMed ID: 9819404
[TBL] [Abstract][Full Text] [Related]
26. Multivalent binding of the ETO corepressor to E proteins facilitates dual repression controls targeting chromatin and the basal transcription machinery.
Guo C; Hu Q; Yan C; Zhang J
Mol Cell Biol; 2009 May; 29(10):2644-57. PubMed ID: 19289505
[TBL] [Abstract][Full Text] [Related]
27. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.
Yan M; Ahn EY; Hiebert SW; Zhang DE
Blood; 2009 Jan; 113(4):883-6. PubMed ID: 19036704
[TBL] [Abstract][Full Text] [Related]
28. Novel RNA-binding properties of the MTG chromatin regulatory proteins.
Rossetti S; van Unen L; Sacchi N; Hoogeveen AT
BMC Mol Biol; 2008 Oct; 9():93. PubMed ID: 18950503
[TBL] [Abstract][Full Text] [Related]
29. Atrophin-1, the dentato-rubral and pallido-luysian atrophy gene product, interacts with ETO/MTG8 in the nuclear matrix and represses transcription.
Wood JD; Nucifora FC; Duan K; Zhang C; Wang J; Kim Y; Schilling G; Sacchi N; Liu JM; Ross CA
J Cell Biol; 2000 Sep; 150(5):939-48. PubMed ID: 10973986
[TBL] [Abstract][Full Text] [Related]
30. A TAF4-homology domain from the corepressor ETO is a docking platform for positive and negative regulators of transcription.
Wei Y; Liu S; Lausen J; Woodrell C; Cho S; Biris N; Kobayashi N; Wei Y; Yokoyama S; Werner MH
Nat Struct Mol Biol; 2007 Jul; 14(7):653-61. PubMed ID: 17572682
[TBL] [Abstract][Full Text] [Related]
31. The AML1/ETO fusion protein activates transcription of BCL-2.
Klampfer L; Zhang J; Zelenetz AO; Uchida H; Nimer SD
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14059-64. PubMed ID: 8943060
[TBL] [Abstract][Full Text] [Related]
32. Eto2/MTG16 and MTGR1 are heteromeric corepressors of the TAL1/SCL transcription factor in murine erythroid progenitors.
Cai Y; Xu Z; Xie J; Ham AJ; Koury MJ; Hiebert SW; Brandt SJ
Biochem Biophys Res Commun; 2009 Dec; 390(2):295-301. PubMed ID: 19799863
[TBL] [Abstract][Full Text] [Related]
33. Nuclear import and subnuclear localization of the proto-oncoprotein ETO (MTG8).
Odaka Y; Mally A; Elliott LT; Meyers S
Oncogene; 2000 Jul; 19(32):3584-97. PubMed ID: 10951564
[TBL] [Abstract][Full Text] [Related]
34. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family.
Gamou T; Kitamura E; Hosoda F; Shimizu K; Shinohara K; Hayashi Y; Nagase T; Yokoyama Y; Ohki M
Blood; 1998 Jun; 91(11):4028-37. PubMed ID: 9596646
[TBL] [Abstract][Full Text] [Related]
35. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
Tanaka K; Tanaka T; Kurokawa M; Imai Y; Ogawa S; Mitani K; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(5):1688-99. PubMed ID: 9473235
[TBL] [Abstract][Full Text] [Related]
36. ETO interacting proteins.
Hug BA; Lazar MA
Oncogene; 2004 May; 23(24):4270-4. PubMed ID: 15156183
[TBL] [Abstract][Full Text] [Related]
37. Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO.
Wichmann C; Grez M; Lausen J
Curr Drug Targets; 2010 Sep; 11(9):1181-91. PubMed ID: 20583973
[TBL] [Abstract][Full Text] [Related]
38. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.
Erickson PF; Dessev G; Lasher RS; Philips G; Robinson M; Drabkin HA
Blood; 1996 Sep; 88(5):1813-23. PubMed ID: 8781439
[TBL] [Abstract][Full Text] [Related]
39. ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein.
Chevallier N; Corcoran CM; Lennon C; Hyjek E; Chadburn A; Bardwell VJ; Licht JD; Melnick A
Blood; 2004 Feb; 103(4):1454-63. PubMed ID: 14551142
[TBL] [Abstract][Full Text] [Related]
40. Tumor suppressor protein p53 recruits human Sin3B/HDAC1 complex for down-regulation of its target promoters in response to genotoxic stress.
Bansal N; Kadamb R; Mittal S; Vig L; Sharma R; Dwarakanath BS; Saluja D
PLoS One; 2011; 6(10):e26156. PubMed ID: 22028823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
